The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 39, No. 7, pp. 1265-1274. DOI 10.1345/aph.1E575
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baker, S. E
Right arrow Articles by Hockman, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baker, S. E
Right arrow Articles by Hockman, R. H.

FORMULARY FORUM

Inhaled Iloprost in Pulmonary Arterial Hypertension

Stacey E Baker, PharmD BCPS

Clinical Pharmacy Specialist, Internal Medicine, Department of Pharmacy Services, University of Virginia Health System, Charlottesville, VA

Rebecca Haynes Hockman, PharmD BCPS

Clinical Pharmacy Specialist, Medical Intensive Care, Department of Pharmacy Services, University of Virginia Health System

Reprints: Dr. Baker, Department of Pharmacy Services, University of Virginia Health System, PO Box 800674, Charlottesville, VA 22908-0674, fax 434/243-9899, seb9r{at}virginia.edu

OBJECTIVE: To review the pharmacology, pharmacodynamics, and clinical trials evaluating inhaled iloprost in pulmonary arterial hypertension (PAH).

DATA SOURCES: A MEDLINE search (1996–February 2005) was performed using the key words pulmonary hypertension, iloprost, and epoprostenol. Information regarding Food and Drug Administration approval was obtained via the Internet.

STUDY SELECTION AND DATA EXTRACTION: All clinical trials using inhaled iloprost in PAH published in English were identified. Additionally, references from the identified articles were reviewed.

DATA SYNTHESIS: A stable analog of prostacyclin, inhaled iloprost is thought to promote benefit in PAH through vasodilation, antiproliferative effects, and inhibition of platelet aggregation. In a placebo-controlled trial of 203 patients, inhaled iloprost significantly improved the combined endpoint of change in New York Heart Association functional class and 10% improvement in 6-minute walk distance (p = 0.007). Small, short-term clinical trials demonstrated hemodynamic benefits for inhaled iloprost alone and in combination with other pulmonary vasodilating agents. The aerosolized delivery route and low incidence of adverse events are positive attributes for inhaled iloprost, while the frequency of administration and lack of comparative data limit its role in PAH.

CONCLUSIONS: Currently, inhaled iloprost offers potential benefit for patients with contraindications to bosentan, preference for non-parenteral products, ineligibility for parenteral therapy, or as adjunctive therapy with other pulmonary vasodilators. Larger, long-term clinical trials are needed to solidify the role for inhaled iloprost in the management of PAH.

Key Words: iloprost, inhaled, prostacyclin, pulmonary hypertension

Published Online, June 7, 2005. www.theannals.com, DOI 10.1345/aph.1E575

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-021-H01


This article has been cited by other articles:


Home page
 Mol. Interv.Home page
B. Rocca
Targeting PGE2 Receptor Subtypes Rather Than Cyclooxygenases: A Bridge Over Troubled Water?
Mol. Interv., April 1, 2006; 6(2): 68 - 73.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.